Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader
2026-03-20 03:25:29 ET
Thesis overview
Boundless Bio ( BOLD ) is a biotech aiming to develop treatments for oncology indications by targeting ecDNA (extrachromosomal DNA)-dependent tumors. Currently, their lead (and only clinical-stage) asset is BBI-940, which aims to eliminate ecDNA from cancer cells by preventing segregation onto chromosomes during mitosis. Following a successful Investigational New Drug ((IND)) application in January , BOLD initiated in February the first phase 1 study of BBI-940 in patients with advanced/metastatic breast cancer, KOMODO-1. First safety and pharmacokinetic/pharmacodynamic data may be available as early as late 2026, while first efficacy data are expected within 2027....
Read the full article on Seeking Alpha
For further details see:
Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader
NASDAQ: BOLD
BOLD Trading
-0.89% G/L:
$1.11 Last:
36,407 Volume:
$1.108 Open:
